genes/EZH2.md
... ...
@@ -0,0 +1,95 @@
1
+---
2
+bibliography: 'morinlab.bib'
3
+csl: 'NLM.csl'
4
+link-citations: true
5
+nocite: |
6
+ @mottokIntegrativeGenomicAnalysis2019, @morinSomaticMutationsAltering2010, @loveGeneticLandscapeMutations2012
7
+---
8
+[[_TOC_]]
9
+
10
+## Overview
11
+EZH2 encodes a histone methyltransferase that is a component of the polycomb repressive complex 2 (PRC2).
12
+This gene is recurrently mutated in both FL and DLBCL and has a common mutation hot spot (Y646) that affects the SET domain.[@morinSomaticMutationsAltering2010]
13
+EZH2 mutations are one of the defining features of the EZB genetic subgroup of DLBCL.[@wrightProbabilisticClassificationTool2020]
14
+Although mutations in EZH2 have been described in some BL patients, they are extremely rare in most BL cohorts that have been sequenced.[@loveGeneticLandscapeMutations2012; @thomasGeneticSubgroupsInform2023]
15
+
16
+
17
+## Experimental Evidence
18
+
19
+Mutations at the main hotspot and some less common hotspots lead to enhanced methylation by PRC2.[@yapSomaticMutationsEZH22011]
20
+A number of small molecule/pharmacologic inhibitors of EZH2 activity have been described.[@garapaty-raoIdentificationEZH2EZH12013; @knutsonSelectiveInhibitionEZH22014] At least one of these, tazemetostat, has shown benefit in FL.[@morinTreatingLymphomaNow2021]
21
+Combination therapies including EZH2 inhibitors are also under exploration for DLBCL patients with mutant EZH2.[@scholzeCombinedEZH2Bcl22020]
22
+
23
+
24
+## Relevance tier by entity
25
+
26
+[[include:tables/table1_EZH2]]
27
+
28
+## Mutation incidence in large patient cohorts (GAMBL reanalysis)
29
+
30
+
31
+### DLBCL
32
+[[include:tables/DLBCL_EZH2.md]]
33
+
34
+### FL
35
+[[include:tables/FL_EZH2.md]]
36
+
37
+### BL
38
+[[include:tables/BL_EZH2.md]]
39
+
40
+
41
+## Mutation pattern and selective pressure estimates
42
+
43
+[[include:tables/dnds_EZH2.md]]
44
+
45
+## EZH2 Hotspots
46
+
47
+| Chromosome |Coordinate (hg19) | ref>alt | HGVSp |
48
+ | :---:| :---: | :--: | :---: |
49
+| chr7 | 148508745 | T>C | N640S |
50
+|chr7|148508740|A>G|F642L|
51
+| chr7 | 148508728 | A>T | Y646N |
52
+| chr7 | 148508728 | A>G | Y646H |
53
+| chr7 | 148508727 | T>G | Y646S |
54
+| chr7 | 148508727 | T>C | Y646C |
55
+| chr7 | 148508727 | T>A | Y646F |
56
+|chr7|148506466|TG>GC|A682G|
57
+|chr7|148506467|G>C|A682G|
58
+|chr7|148506437|GC>AA|A692L|
59
+|chr7|148506437|G>A|A692V|
60
+
61
+[[include:tables/browser_EZH2.md]]
62
+
63
+## Expression
64
+![](images/gene_expression/EZH2_by_pathology.svg)
65
+
66
+## Representative Mutations
67
+
68
+### BL
69
+
70
+![](primary/Love_EZH2.svg)
71
+**Rating**
72
+★ ★ ★ ★ ★
73
+
74
+## All Mutations
75
+
76
+### BL
77
+
78
+[@loveGeneticLandscapeMutations2012]
79
+
80
+[1092](https://www.bcgsc.ca/downloads/morinlab/GAMBL/Love/1092_reports.html)
81
+[671](https://www.bcgsc.ca/downloads/morinlab/GAMBL/Love/671_reports.html)
82
+[672](https://www.bcgsc.ca/downloads/morinlab/GAMBL/Love/672_reports.html)
83
+[675](https://www.bcgsc.ca/downloads/morinlab/GAMBL/Love/675_reports.html)
84
+
85
+<!-- ORIGIN: morinSomaticMutationsAltering2010 -->
86
+<!-- BL: loveGeneticLandscapeMutations2012 -->
87
+<!-- FL: morinSomaticMutationsAltering2010a -->
88
+<!-- BL: loveGeneticLandscapeMutations2012 -->
89
+<!-- DLBCL: morinSomaticMutationsAltering2010 -->
90
+<!-- PMBL: mottokIntegrativeGenomicAnalysis2019b -->
91
+
92
+[[include:tables/mermaid_EZH2.md]]
93
+
94
+## References
95
+